Skip to main content

Advertisement

Table 2 Association of the coefficient score with disease-specific survival in the study cohort and the validation cohort

From: A prognostic CpG score derived from epigenome-wide profiling of tumor tissue was independently associated with colorectal cancer survival

Patient groupsSubgroupsTertile groups (cutoff points)Study cohortValidation cohort
NDeaths (%)HR (95% CI)ap value of trendNDeaths (%)HR (95% CI)ap value of trend
All patients Tertile 319536 (18)Ref. 12425 (20)Ref. 
Tertile 2 (− 4.32247)18831 (16)1.31 (0.80–2.15) 8922 (25)1.66 (0.91–3.05) 
Tertile 1 (− 3.92950)18569 (37)3.16 (2.08–4.80)< 0.00019535 (37)2.75 (1.56–4.85)0.0004
Microsatellite instabilityMSSTertile 317535 (20)Ref. 11425 (22)Ref. 
Tertile 2 (− 4.32247)16129 (18)1.31 (0.79–2.17) 7921 (27)1.63 (0.88–3.01) 
Tertile 1 (− 3.92950)16766 (40)3.11 (2.04–4.76)< 0.00018933 (37)2.65 (1.49–4.72)0.0009
MSI-HTertile 3201 (5)Ref. 100 (0)Ref. 
Tertile 2 (− 4.32247)272 (7)NC 101 (10)NC 
Tertile 1 (− 3.92950)183 (17)NCNC62 (33)NCNC
BRAF mutationNegativeTertile 318534 (18)Ref. 11522 (19)Ref. 
Tertile 2 (− 4.32247)17128 (16)1.23 (0.74–2.07) 8119 (23)1.53 (0.81–2.91) 
Tertile 1 (− 3.92950)16661 (37)3.24 (2.09–5.02)< 0.00019334 (37)2.72 (1.53–4.85)0.0007
PositiveTertile 3102 (20)Ref. 93 (33)Ref. 
Tertile 2 (− 4.32247)173 (18)NC 83 (38)NC 
Tertile 1 (− 3.92950)198 (42)NCNC21 (50)NCNC
Tumor locationProximal colonTertile 3595 (8)Ref. 4010 (25)Ref. 
Tertile 2 (− 4.32247)8011 (14)2.60 (0.87–7.84) 276 (22)0.99 (0.31–3.13) 
Tertile 1 (− 3.92950)7125 (35)6.92 (2.46–19.4)< 0.00014114 (34)2.05 (0.79–5.34)0.1176
Distal colonTertile 37119 (27)Ref. 415 (12)Ref. 
Tertile 2 (− 4.32247)495 (10)0.73 (0.25–2.14) 268 (31)1.76 (0.51–6.09) 
Tertile 1 (− 3.92950)5620 (36)2.03 (1.05–3.94)0.0477218 (38)6.00 (1.61–22.4)0.0098
Rectum proximalTertile 36512 (18)Ref. 4310 (23)Ref. 
Tertile 2 (− 4.32247)5915 (25)1.36 (0.62–3.01) 368 (22)3.48 (0.97–12.4) 
Tertile 1 (− 3.92950)5824 (41)3.59 (1.64–7.87)0.00123313 (39)4.02 (1.38–11.7)0.0129
  1. Abbreviations: CI confidence interval, HR hazard ratio, NC not calculated (< 5 patients)
  2. aCox regression adjusted for age, sex, tumor stage, tumor location, chemotherapy, MSI status, and BRAF mutation status